Browsing Clinical Studies by author "Hall, Emma"
Now showing items 81-100 of 126
-
Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer.
Hague, C; Foran, B; Hall, E; Guild, S; Joseph, O; et al. (ELSEVIER SCIENCE LONDON, 2018-05-01) -
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart, RA; Hall, E; Lewis, R; Porta, N; Crundwell, M; et al. (ELSEVIER, 2020-02-01)BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant ... -
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Yap, TA; Kristeleit, R; Michalarea, V; Pettitt, SJ; Lim, JSJ; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-01)Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing ... -
Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Tandogdu, Z; Lewis, R; Duncan, A; Penegar, S; McDonald, A; et al. (BMJ PUBLISHING GROUP, 2019-09-03)INTRODUCTION: Bladder cancer is the most frequently occurring tumour of the urinary system. Ta, T1 tumours and carcinoma in situ (CIS) are grouped as non-muscle invasive bladder cancer (NMIBC), which can be effectively ... -
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer, R; Lewis, R; Duncan, A; Penegar, S; Vadiveloo, T; et al. (NIHR JOURNALS LIBRARY, 2022-10-01)BACKGROUND: Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule ... -
PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018).
Syndikus, I; Cruickshank, C; Staffurth, J; Tree, A; Henry, A; et al. (ELSEVIER IRELAND LTD, 2020-11-01)•PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select ... -
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; et al. (ELSEVIER, 2018-09-01)BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ... -
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love, SB; Cafferty, F; Snowdon, C; Carty, K; Savage, J; et al. (BMC, 2022-09-06)BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are ... -
Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?
Thompson, MK; Poortmans, P; Chalmers, AJ; Faivre-Finn, C; Hall, E; et al. (NATURE PUBLISHING GROUP, 2018-08-14)As we mark 150 years since the birth of Marie Curie, we reflect on the global advances made in radiation oncology and the current status of radiation therapy (RT) research. Large-scale international RT clinical trials have ... -
Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance.
Hafeez, S; Patel, E; Webster, A; Warren-Oseni, K; Hansen, V; et al. (BMJ PUBLISHING GROUP, 2020-05-26)INTRODUCTION: Patients with muscle invasive bladder cancer (MIBC) who are unfit and unsuitable for standard radical treatment with cystectomy or daily radiotherapy present a large unmet clinical need. Untreated, they suffer ... -
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance.
Hafeez, S; Webster, A; Hansen, VN; McNair, HA; Warren-Oseni, K; et al. (BMJ PUBLISHING GROUP, 2020-12-31)INTRODUCTION: Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following ... -
Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit.
National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group, (ELSEVIER SCIENCE LONDON, 2018-05-01)The use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients. However, it is associated with a high capital cost and the need to build new ... -
Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer.
Tyler, J; Bernstein, D; Seithel, M; Rooney, K; Petkar, I; et al. (ELSEVIER, 2021-10-01)This study aimed to assess the impact of the margin applied to the clinical target volume, to create the planning target volume, on plan quality of a novel dysphagia-optimised intensity modulated radiotherapy technique ... -
Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module.
Patel, E; Tsang, Y; Baker, A; Callender, J; Hafeez, S; et al. (ELSEVIER IRELAND LTD, 2019-11-01)BACKGROUND AND PURPOSE: Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating "Plan of the Day" (PoD) adaptive radiotherapy for bladder cancer. ... -
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.
Verkooijen, HM; Kerkmeijer, LGW; Fuller, CD; Huddart, R; Faivre-Finn, C; et al. (FRONTIERS MEDIA SA, 2017-04-03)The pace of innovation in radiation oncology is high and the window of opportunity for evaluation narrow. Financial incentives, industry pressure, and patients' demand for high-tech treatments have led to widespread ... -
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; et al. (OXFORD UNIV PRESS INC, 2020-02-01)BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk ... -
Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
Naismith, O; Mayles, H; Bidmead, M; Clark, CH; Gulliford, S; et al. (ELSEVIER SCIENCE LONDON, 2019-09)AIMS: The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed ... -
Radiotherapy Trial Set up in the UK: Identifying inefficiencies and potential solutions
Hall, E (Elsevier, 2019-11-01) -
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Parker, C; Tunariu, N; Tovey, H; Alonzi, R; Blackledge, MD; et al. (OXFORD UNIV PRESS, 2023-10-31)BACKGROUND: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation ... -
RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
Wilkins, A; Hall, E; Lewis, R; Gribble, H; Melcher, A; et al. (ELSEVIER SCIENCE LONDON, 2022-07-01)